Navigation Links
Bionovo Announces 2009 Highlights and Year-End Financial Results
Date:3/15/2010

ntial pharmacological uses. In addition, our studies have indicated that these compounds do not promote breast or endometrial cancer in animal models, unlike estrogen therapies. This suggests that these ER beta-selective compounds could lead to safer, more appealing therapies for menopausal disorders.
  • Publication of final study results from our Phase 1B trial of Bezielle for metastatic breast cancer. Bezielle showed an excellent safety and tolerability profile. It also showed promising early efficacy in a difficult-to-treat population, including stable disease and tumor regression.
  • International presentation of final study results from our Phase 2 trial of Menerba for menopausal vasomotor symptom treatment. These results included:
    • After 12 weeks of treatment, there was a statistically significant decrease in frequency of all hot flashes in the higher dose of Menerba (p=0.04).
    • There was a clear dose response trend in multiple efficacy analyses.
    • Menerba reduced the number of times women were awakened from sleep due to hot flashes (night sweats). The median percent reduction in night sweats in the higher dose of Menerba was 67%, statistically superior to placebo (p=0.05).
    • Compliance and study retention was excellent: 98% of participants completed the trial, with 91% of participants taking at least 75% of the assigned study medication.
    • The only statistically significant adverse event was "transient loose stools" (12% on Menerba vs. 3% on placebo).
    • During the trial, there was no difference in the number of uterine bleeding episodes between the treatment g
      '/>"/>

    SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
    2. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
    3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
    4. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
    5. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
    6. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
    7. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
    8. Bionovo Announces First Quarter 2009 Highlights and Financial Results
    9. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
    10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
    11. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
  • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014  Endo ... ENDP ) (TSX: ENL), and BioDelivery Sciences ... that they have submitted a New Drug Application (NDA) ... and Drug Administration (FDA).  Buprenorphine HCl Buccal Film is ... to require daily, around-the-clock, long-term opioid treatment and for ...
    (Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
    (Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
    Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
    ... Inc. (NASDAQ: SSRX ) ("3SBio" or "the ... developing, manufacturing and marketing biopharmaceutical products, today announced that ... after the NASDAQ stock market closes on Monday, August ... Following the earnings announcement, 3SBio,s senior management will host ...
    ... July 21, 2011 Dr. Kaveh Kardooni ... specializing in Neuroradiology. Dr. Kardooni graduated from ... of science in biology. He received his medical degree ... Dr. Kardooni completed his diagnostic radiology residency in 2009 ...
    Cached Medicine Technology:3SBio Inc. Schedules Unaudited Second Quarter 2011 Results 2Desert Radiologists Welcomes Dr. Kaveh Kardooni 2
    (Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
    (Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
    (Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
    (Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
    (Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
    Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
    ... Feb. 9 (HealthDay News) -- A growing number of Americans ... social networking sites rather than friends, a new survey ... information from social media such as Facebook and Twitter, a ... number of patients who sought information from friends fell from ...
    ... Moffitt Cancer Center in Tampa, Fla., have discovered that ... roles in tobacco-related non-small cell lung cancers. Tobacco carcinogens ... The study was published in a recent issue ... identified oconogene, a gene linked to cancer," said study ...
    ... certain cancer cells may exhibit greater flexibility than normal ... tumor growth. Now computer simulations developed by Boston University ... the University of Texas at Austin appear to support ... cells that they,ve created indicates that the softening of ...
    ... 9, 2012) In a study to be presented ... The Pregnancy Meeting , in Dallas, Texas, researchers will ... delivery via cesarean section appear to know little about ... second cesarean or trial of labor to attempt a ...
    ... Fla. and ORLANDO, Fla. Moffitt Cancer Center, ... announced they will collaborate on the creation of ... The partnership will conduct collaborative research to accelerate ... of cancer and metabolic diseases, including obesity, diabetes ...
    ... SAN FRANCISCO There is growing evidence that supports an association ... the thigh bone, typically without trauma and the use ... fracture incidence caused by osteoporosis. While the risk for suffering ... small just 1 in 1,000 patients after six years ...
    Cached Medicine News:Health News:More Patients Seek Plastic Surgery Advice From Facebook, Twitter 2Health News:Researchers find important 'target' playing role in tobacco-related lung cancers 2Health News:Boston University research suggests new pathways for cancer progression 2Health News:Study finds pregnant women with prior cesarean choose the delivery method preferred by their doctor 2Health News:Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida 2Health News:Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida 3Health News:Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half 2
    Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
    For the quantitative in vitro determination of Ammonia in plasma...
    Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
    Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
    Medicine Products: